Substance Dependence Clinical Trial
Official title:
Brain Mechanism and Intervention of Executive-control Dysfunction Caused by Impaired Prefrontal-ventral Striatum Synchronization Among Substance Dependents
The investigators assume that tACS could improve amphetamine and alcohol dependent patients' executive-control function by adjusting the synchronization patterns and enhancing the functional connectivity of the prefrontal-ventral striatum pathway. A random controlled trial will be used to test the effect of θ-tACS treatment. Three months follow-up assessment will be conducted to test the changing of executive-control function and its mechanism.
Substance abuse has become a major social and public health problem in China, especially for amphetamine abuse and alcohol abuse. Executive-control dysfunction is the main symptom for substance dependents. Previous studies have demonstrated the relationship between cognitive dysfunction and prefrontal-ventral striatum pathway. Studies have shown that abnormal phase synchronization and phase-amplitude coupling (PAC) induced the impairment of cognitive, and tACS could improve executive-control function by adjusting the abnormal synchronization. But it has not been verified among MA or alcohol patients. The investigators assume that tACS could improve MA and alcohol dependent patients' executive-control function by adjusting the synchronization patterns and enhancing the functional connectivity of the prefrontal-ventral striatum pathway. A random controlled trial will be used to test the effect of θ-tACS treatment. Three months follow-up assessment will be conducted to test the changing of executive-control function and its mechanism. This study will provide a practical and theoretical basis for developing a novel treatment for substance dependents. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00887367 -
EtOH Interaction Study
|
Phase 1 | |
| Completed |
NCT01036061 -
GSK618334 Repeat Dose Study
|
Phase 1 | |
| Completed |
NCT01189799 -
Motivational Therapy for Substance Users With Depression
|
N/A | |
| Completed |
NCT01381133 -
Adolescent Outpatient and Continuing Care Study
|
Phase 3 | |
| Recruiting |
NCT04430257 -
Pre-exposure Prophylaxis (PrEP) for Health
|
N/A | |
| Completed |
NCT01128140 -
Efficacy Trial of Warrior Check-Up
|
Phase 2 | |
| Completed |
NCT03767907 -
Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial
|
N/A | |
| Recruiting |
NCT05833399 -
Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
|
||
| Withdrawn |
NCT01515917 -
Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)
|
N/A | |
| Completed |
NCT00208143 -
Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
|
Phase 4 | |
| Withdrawn |
NCT03762798 -
Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone
|
N/A | |
| Completed |
NCT03048552 -
Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3
|
N/A | |
| Active, not recruiting |
NCT04768920 -
Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD)
|
N/A | |
| Recruiting |
NCT05410561 -
Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients
|
N/A | |
| Recruiting |
NCT05679284 -
A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
|
||
| Withdrawn |
NCT00908206 -
Effects of GSK598809 on Brain Activation in Abstinent Alcoholics
|
Phase 1 | |
| Recruiting |
NCT05348317 -
Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders
|
N/A | |
| Recruiting |
NCT01741415 -
Distress Tolerance Treatment for Substance Users
|
Phase 2 | |
| Active, not recruiting |
NCT01621711 -
Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care
|
N/A | |
| Active, not recruiting |
NCT00609089 -
Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction
|
Phase 1/Phase 2 |